Currently
The two most common first-line chemotherapy combinations used for pancreatic cancer are (1) FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) and (2) gemcitabine plus nab-paclitaxel.
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer (onivyde)
Our Dep Irinotecan mono and combination drug will become the new standard of care -against pancreatic cancer with better efficacy and very little side effects compared to the above black box label drugs
Currently The two most common first-line chemotherapy...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.27M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.81K | 419.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 495105 | 3 |
View Market Depth
| Last trade - 14.22pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |